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Abstract
Patients with neuromuscular disease (NMD) requiring tracheostomy and mechanical
ventilation secondary to respiratory failure encounter increased difficulty in removing pulmonary
secretions from the airways. To combat issues associated with current treatment modalities for
insufficient cough efficacy (cost, poor mobility, discomfort, lack of evidence), we have
developed an instrumentational proximal airway clearance technique (ACT) which augments a
manual proximal ACT developed by a client with NMD. QuickCough is a 3D-printed PLA
attachment to the tracheostomy apparatus which has demonstrated its ability to facilitate pressure
changes necessary to increase patient’s peak cough flow (PCF) by providing a stronger
exsufflation for the patient. QuickCough meets client needs by providing a machine-washable,
inexpensive method of facilitating secretion expulsion without the use of bulky equipment intransit. This novel instrumentational augmentation of a manual ACT was designed using the
engineering design process discussed in The University of Akron’s biomedical engineering
design course 4800:470. Future work ought to focus on development of an automated procedure
to allow application of QuickCough in cases of global paralysis or insufficient home-care.

Description of the Project Problem
Patients who are no longer able to carry out normal respiration may require respiratory
support with the use of a tracheostomy [1], which is a surgical procedure performed to bypass
the upper airway and create access to apply ventilatory respiratory support [2]. A modified
endotracheal tube is then inserted through the tracheostomy to maintain the airway indefinitely
(Figure 1a). A small balloon at the distal end of the tracheostomy tube (TOT) is inflated with
saline to maintain a sufficient seal and prevent aspiration (Figure 1b). Tracheostomy is
accompanied by mechanical ventilation through the tracheostomy apparatus by an external
pump,
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Figure 1. (a) Image of a tracheostomy tube being passed through the tracheostomy incision of canine model
(https://ccforum.biomedcentral.com/articles/10.1186/cc4926). (b) Illustration of implanted tracheostomy tube, highlighting location of exterior
port and presence of saline-inflated balloon distally (https://www.mayoclinic.org/tests-procedures/tracheostomy/about/pac-20384673).

which facilitates the respiratory cycle and maintains homeostatic gas exchange [3]. Illustrations
of these devices are shown in Figure 2. Short-term utilization of tracheostomy for mechanical
ventilation may be indicated in young or healthy patients who have undergone acute trauma,
extensive surgery, or have a tortuous upper airway preventing traditional endotracheal intubation
(see Figure 2) [4-6]. The most common indication for long-term mechanical ventilation is acute
respiratory failure [7], which may be caused by infection, major adverse cardiovascular events,
worsening of chronic respiratory disease, acute asthma, trauma, neuromuscular disease (NMD),
or a combination of these [8, 9]. Tracheostomy is currently the best modality for long-term
mechanical ventilation, as traditional endotracheal intubation poses a number of threats to the
patient in long-term use [10, 11]. Despite the benefits of tracheostomy in long-term management
of respiratory failure, there are several significant adverse events which may occur in patients
with tracheostomy, which are reviewed in depth by Stauffer et al [11]. The scope of this project
pertains to patients with acute respiratory failure secondary to neuromuscular disease, and the
subsequent inability to expel secretions from the respiratory tract; therefore, please refer to the
aforementioned review [11] for additional information.

Figure 2. (a) Tracheostomy tube with components. Note the saline-inflated balloon at the distal end of the device, as well as two sleeve
components for surgical placement (https://www.hopkinsmedicine.org/tracheostomy/about/types.html). (b) Mechanical ventilation machine. A
device such as this is typically found in the home of mechanically-ventilated patients (https://www.sonashomehealth.com/medical-ventilator/). (c)
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Traditional endotracheal intubation. Note the passage of the artificial airway through the vocal cords as opposed to a surgical incision through the
anterior neck. In a tortuous airway, passing the endotracheal tube may be harmful or impossible (https://emedicine.medscape.com/article/109739overview).

Patients with NMD are at increased risk of respiratory-related mortality due to
diminishing gas exchange and inability to remove airway secretions [12]. Tussis, or coughing, is
a mechanism by which airway secretions are expelled to prevent infection, acidosis, hypoxia,
atelectasis, or obstruction [13]. In conjunction with progressive neuromuscular pathology,
undergoing TOT placement presents anatomical and physiologic changes which may disturb or
burden the cough cycle. In the setting of progressive neuromuscular disorder, patients may have
weakened inspiratory and expiratory muscle groups preventing large-volume exsufflation
required to expel pulmonary secretions [13-15]. Secretion burden is exacerbated by placement of
a TOT, which causes excess tracheal secretion build-up in and around the TOT despite
traditional preventative measures such as suction or humidification [16-20]. Complications
related to secretion build-up include TOT blockage and life-threatening infection caused by
retained microorganisms [16, 21-24].
Many techniques are available to augment the coughing mechanism for NMD patients
who are mechanically ventilated through tracheostomy (NMDmvT), which are well-reviewed by
Chatwin et al [25]. Briefly, assisted cough techniques (ACTs) may be designated into two
categories. Proximal ACTs directly impact the patient’s peak cough flow (PCF) by aiding in
inspiratory or expiratory pressures. The scope of this project centralizes around adverse events
associated with the use of a mechanical insufflation-exsufflation (MI-E) device, which aims to
replicate the airflow seen in a normal cough by augmenting inspiration with positive-pressure,
followed rapidly by negative-pressure to force the air out of the lungs. This modality is
commonly indicated in NMDmvT patients, who have poor inspiratory and expiratory
performance [25-27]. These devices are unable to provide mobile care given their size and are
often limited to the confines of a home or hospital suite. Complications of this technique are
uncommon but significant [28, 29], the most immediate concern being thoracic wall discomfort
and anxiety with loss-of-control of the respiratory cycle [13]. Additionally, MI-E devices are
costly, and may not be reimbursed or available in certain regions [25, 26].
Peripheral ACTs indirectly improve cough efficacy by loosening and mobilizing
secretions from small airway structures into large airways, which allows for more clearance
during cough cycles [30]. The two peripheral ACTs contested in the scope of this project are the
use of a high frequency chest wall oscillation (HFCWO) vest, and development of a manual
technique to loosen secretions. These items will be further described in the background section
of this report. Instrumentation for peripheral ACTs are limited by high cost, routine need for
subsequent use of a proximal ACT, and risk of respiratory arrest secondary to sudden
mobilization of large-volume secretions into major airways [25, 31, 32]. Pitfalls of manual
peripheral ACTs include insufficient evidence-based medicine directing their use in NMD and
poor understanding of physiologic effects [25]. Particularly in moderate-to-severe NMD, a
limitation of all present ACTs is the need for a caretaker to assist with or perform the technique.
In light of the current modalities and limitations of airway clearance in patients with
NMD, a clear subset of NMDmvT patients are identified as underequipped for management of
airway secretions. Many NMDmvT patients may still be attending school, even at the collegiate
level, and require the resources to perform adequate airway clearance outside of their primary
care center or home. Many of these patients use instrumentational or manual peripheral ACTs in
conjunction with suctioning, but as previously discussed, is not as effective as techniques such as
MI-E [25, 26, 33, 34]. Patients who note anxiety or discomfort with more invasive modalities
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also ought to have a sufficient manual technique which provides them with the sense of control
and security needed to maintain cooperativity and effectiveness of treatment. Throughout the
course of this project, we aimed to develop a solution which addresses the main problems
addressed throughout this section, as well as additional well-known concerns: cost, portability,
ease-of-use, sterility, and production of adequate pressure waveform to generate effective airway
clearance. The scope of this project centers around mild-to-moderate cases of NMD in which
patients have some independence of respiratory-related muscle groups. Prognostically, NMD
patient conditions will continue to progressively worsen and require more aggressive
management of respiratory failure throughout disease development [35].

Background
The client for this project is a 22-year-old male with progressive NMD who, for the past
7 years, has required mechanical ventilation through his tracheostomy tube secondary to NMDassociated respiratory failure. Secondary to global neuromuscular decomposition, he depends on
mobility through use of a motorized chair, as well as direct care with the help of a family
caretaker. Despite his disabilities, the client is an active student at a nearby university, attending
classes regularly and involved in extracurricular activities. He follows up for respiratory care at a
nearby pediatric tertiary care center, where he has received his care since notable onset of NMDrelated symptoms and respiratory insufficiency. The client’s respiratory management over the
past several years has been widely variable, and significant complications of his disease have
included numerous admissions over the past several years related to secretion burden in the
central airways. At home, he uses a currently marketed MI-E device for proximal airway
clearance, as well as a HFCWO vest for peripheral support; however, the MI-E device is
associated with thoracic wall discomfort and emotional stress and during use, forces his caretaker
to disconnect his ventilation tube, and decreases his mobility while transitioning from home to
school. Unfortunately, the utilization of multiple instrumentational techniques has not eliminated
pneumonia-related admissions.
Approximately 1 year ago, the client developed a personalized manual technique that he
uses frequently with great success. Briefly, the client removes the ventilation tubing from the
lateral aspect of the tracheostomy hardware; he is able to maintain his airway for several minutes
without direct ventilatory support. Following separation with the ventilation pump, the client
seals the small opening on the tracheostomy apparatus with his thumb. Simultaneously, the
caretaker connects a vacuum pump to the end of the tracheostomy port perpendicular to the
anterior neck, which contains a small catheter that can advance into the central airways to suction
out secretions. As the vacuum pump is inducing negative pressure in the airways, the client’s
thumb-seal allows this negative pressure to build up inside of the airways. The client has
performed this technique enough times such that he is able to feel an increasing degree of suction
imposed on the thumb sealing the ventilation port. The client releases the thumb-seal at a selfdefined level of suction felt on his thumb, which forces a rapid elimination of the negative
pressure gradient and seemingly augments a strong exsufflation as described in the problem
description section of this report. As a result of this pressure change, secretions are believed to
move proximally and eventually into the suctioning device, clearing the central airways after
multiple cycles of the technique. He is able to perform this anywhere, provided he has the
necessary assistance. The client claims he has had no pneumonia-related admissions since
development of this technique. Despite the technique’s success, the client and his caretaker are
not satisfied with the need for assembly deconstruction prior to technique performance.
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Design Requirements for Project Specification
There were fifteen design requirements that were used to develop QuickCough. These
requirements and their descriptions can be seen in Table 1 below.
Table 1: Design Requirements
Requirement

Purpose

Numerical Value

QuickCough cannot exceed the
mean weight of provided ventilator
attachments.

Ensures that the device will not
weigh down the tracheostomy port
and ventilator tubing.

Mean weight of
ventilator
attachment: 11.9 g

QuickCough must be no larger than
the largest ventilator adaptor
provided by the client.

Ensures that the device will not
Dimensions of
interfere with the tracheostomy port largest ventilator
and ventilator tubing.
adaptor: 8.5 cm x
4 cm x 4.5 cm

QuickCough must provide an
airtight seal when activated.

An airtight seal is essential to
In a bubble test, 0
generating a negative pressure in
bubbles must be
the lungs to increase the efficacy of generated
secretion expulsion. This was tested
by submerging the device in water
and blowing air through the device
to see if any bubbles were
generated.

QuickCough cannot decrease the
tidal volume of the patient.

The device is intended to be worn at
all times and that would not be
possible if it was impeding the flow
of air to the client.

QuickCough must be compatible
with the tracheostomy port,
ventilator tubing and ventilator
attachments.

For the device to be used properly, Outlet
it must live in line with the
- OD 1.9 cm
ventilator tubing, attachments and
- ID 1.7 cm
tracheostomy port, which is
Intlet
measured by the outer diameter
- OD 1.5 cm
(OD) and inner diameter (ID) of the
- ID 1.3 cm
tubing.

Patient’s tidal
volume should not
be less than 207
ml per inspiration
(Dexter, 2018)
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QuickCough must be easily
activated.

The device is intended to be used
by a caregiver or the patient
themselves so it must not require
much force to compress the button.
It requires 12.9 N to hit a keystroke
(Dennerlein, 2009) so this amount
of force or less is acceptable for the
user to expend when using the
device.

The force required
to hit a keystroke:
12.9 N

QuickCough must be able to
withstand a life cycle of 1 month.

A greater life cycle would require
fewer replacements for the client.
Every three days, the client expels
secretions 100 times. So, in a 30day month, the client will use the
device about 1,000 times.

Number of
compressions
required to
simulate one
month of use and
wear: 1000
compressions

QuickCough must be able to
withstand a shelf life of 2 years.

A shelf life of 2 years allows for the Required shelf
device to be produced in bulk about life: 2 years
once a year, instead of creating a
new device each month.

QuickCough must generate a
breathing waveform, as seen in
other devices that occludes airway,
when attached to a lung simulator.

This waveform ensures that a
Visual inspection
proper seal is generated and that the and analysis of
device will not hurt the patient
data from testing
with Ms. Volsko
at Akron
Children’s
Hospital

QuickCough must have a safety
feature which prevents
unintentional activation.

Safety is always the highest priority
and a failsafe must always be
included in a device.

N/A

QuickCough must be made of a
material which can withstand high
temperatures for cleaning within a
dishwasher.

The device must be easily cleaned.
The average maximum temperature
a dishwasher reaches is 180 ℉ [36]

Washing machine
maximum
temperature: 180
℉

QuickCough must be made of a
material which does not induce an
immune response when in contact
with the patient.

As this device will always be in
contact with the patient, it is
important that the material in the
device does not irritate the user.

N/A
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QuickCough must be made of a
material which is disposable.

Ensures that the device is nonhazardous waste and can be
disposed of in a trashcan.

N/A

QuickCough must be easily
manufactured by 3D printing.

Ensures low cost and ease of
building.

N/A

QuickCough must allow the user to
feel how much pressure is being
applied when it is activated.

Currently, the user is able to feel
N/A
how much pressure is being
generated on their thumb when they
perform this technique. The client
would like to keep this feature.

Test
The device underwent 27 test cases, categorized in Table 2. Each evaluation method had
qualitative or quantitative criteria for success. The device passed each test case described in
Table 2 unless discussed below. The device failed 2 tests, had 6 acceptable failures (equivalent
passes), and passed the remaining 19 tests. In depth descriptions and results of each test are
found in the Appendix.

Acceptable Failures
The first acceptable failure is that the device is not entirely 3D printed. This is acceptable
because the screws and tubing are easily acquired and assembled. Another acceptable failure is
the size of the device, which does not exceed 2 centimeters past the criteria in any dimension. It
is also acceptable that the silicone tubing failed in pushing the plunger back up in 5 seconds, as it
was able to return to neutral position in 8 seconds. The device required more than 12.9 N to
depress the plunger, but this result is an acceptable failure because the human factors test
subjects were able to depress the plunger without undue burden and there was insufficient
equipment to test this case. Similarly, the device acceptably failed shelf life and lifecycle testing
due to inaccessibility of equipment.

Failures
The device failed the weight test case and is approximately 6 times the goal weight. The
goal weight is the mean weight of provided ventilator equipment, 12 grams, while the device
weighs approximately 70 grams. Another failure of the device is its inability to provide tactile or
electronic pressure feedback. These items could be fixed in a second version of this product, but
cannot be addressed at this time.
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Table 2. Testing results (summarized into categories).
Test Category

Evaluations

Marketing and The device comes with instructions or graphics on the device to ensure
Manufacturing proper use, is not easily manufactured via 3D printing, is easy to replace, is
easy to use, and is not difficult to train people to use
Measurement

The device is 1.4 times larger than the largest device attachment the
customer provided us, is easy to transport, and weighs about 6 times more
than the heaviest attachment.

Material
Analysis

The device is biocompatible, is compatible with air, is compatible with
water, can withstand machine washing in a dishwasher, is disposable after a
certain period of use, does not contain any electrical components, and does
not collect data.

Occluding the
airway

The airway is instantaneously blocked when the user wishes to close the
airway and there is a way to ensure that the device will never lock in the
closed position. The silicone tubing takes 8 seconds to push the button back
into a neutral position, more than 12.9 N is required to compress the button
and plunger, and the user is not able to physically feel how much pressure is
being applied. The device will create a pressure waveform, does not leak
any air, does not restrict airflow, and is comfortable to use.

Fit with
attachments

The device fits in line with the ventilation tube and with other ventilation
tube adaptors

Wear on the
device

We were unable to test if the device can withstand a 1 month of use or has a
shelf life of 2 years.

Business Aspects
QuickCough’s similarity with the component for Haylard’s closed suction tracheostomy
tube make it possible to run into patent laws for the design, which could pose an issue to sell this
product commercially. However, if a patent lawyer was consulted with and the device was
deemed fit for patentability the following plan would be implemented. QuickCough is specific
for those who are able to have at-home care with a ventilator. The transition from the hospital to
the home follows a strict protocol, with the fifth mentioning home equipment (HME) companies,
“Provide HME company with a list of equipment and supplies” [37]. These HME companies
would ultimately be the entities which would pay us. The goal would be to leverage a business to
business approach, targeting the companies so we can reach the largest number of patients.
QuickCough would be patented and the rights would be leased to the HME companies so that
they will be the ones creating the physical product. Revenue would be made through the lease by
per-unit sales royalties and twice a year the leasing contract would expire so that the royalties
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can be adjusted for inflation and other economic variables. The profit will be maximized and
overhead reduced since we eliminate the need for a distribution network by leasing the design.
Additionally, marketing, advertising and promoting would be the responsibility of the lessee.
After review of the initial business proposal outlined in a presentation on March 11th, 2019 and
summarized in the paragraph above, the team has decided that no further updates/alterations are
necessary.

Final Implementation
Our final design for the QuickCough mechanism is displayed in the expanded drawing
below (Figure 3). The device consists of a lower housing (part 8), which is 3D printed, holds the
silicone tubing (part 7) in place, and allows for ventilation tubing and other attachments to fit
onto either end of the device. The upper housing (part 6) is also 3D printed and connects to the
lower housing with four screws (parts 1). There is a slot through the middle of this upper
housing, which allows for the plunger (part 5) to move vertically and compress the silicone
tubing when a user depresses it. The cap (part 4) attaches to the plunger with a screw. This piece
provides comfort for the user and ensures a firm grip on the device. The safety cage (parts 3)
snugly fits around the neck of the plunger with the use of neodymium magnets (parts 2) to
prevent the plunger from being compressed and closing the patient’s airway prematurely or
permanently. The safety cage must be on the device at all times and should be removed before
use. Detailed drawings of each assembly can be found in the Section E of the Appendix.

Figure 3. Exploded view of the device. 1 - Self-tapping screws. 2 - Neodymium magnets with adhesive. 3- Safety cage. 4 - Top cap for plunger. 5
- Plunger Body. 6 - Upper housing of main body assembly. 7 - Silicone tubing. 8 - Lower housing of main body assembly.
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The device will remain attached to the patient’s tracheostomy port at all times, except
when it needs disconnected for regular cleaning and maintenance. When a user wants to use this
device, they will remove the safety cage from the plunger and compress the device for no longer
than 16 seconds. When an appropriate level of negative pressure is achieved (this is to be
determined by the client and their comfort level), the user will release the button and air from the
ventilator will be reintroduced to the client’s lungs. After use, the safety cage must be reattached
to the neck of the plunger.
A description of airflow through the device can be found in the below block diagram
(Figure 4). Air will begin at the ventilator and travel through the input of the device. If the client
does not wish to expel secretions from their lungs, the safety guard will remain on the device,
which will prevent the button and plunger from being compressed. The air will continue its
journey through the silicone tubing (located in the housing), leave the device through the outlet,
and eventually travel into the user’s lungs. Air can then be exhaled from the lungs by traveling in
the opposite direction out of the device and back towards the ventilator. If the user wishes to
expel secretions from the lungs, the user will remove the safety guard and compress the newlyfreed button. This button will depress the plunger and pinch the silicone tubing, creating a seal.
At the same time, one end of the tracheostomy port will be hooked up to a pump, which is
constantly running and trying to pull secretions from the lungs. The combination of this pump
(which is removing air from the lungs) and the seal within the device (which prevents air from
entering the lungs) creates a negative pressure in the lungs. This negative pressure is used to
draw mucous in the lungs towards the bronchial tubes and eventually sucked out by the pump,
simulating a cough. When an appropriate level of negative pressure is created (as defined by the
patient), the button can be released so that air will re-enter the lungs. This process can then be
repeated to expel more secretions, or the safety guard can be replaced and allow the user to
breathe normally until the next time secretions must be expelled.

Deliverables
Year-long deliverables to both the professor and to the client are outlined in our
Memorandum of Understanding (MOU). Deliverables to the advisor include the design history
file, the NABC (Need, Approach, Benefits, and Competition) project sheet, project
specifications, the initial drawings, meeting minutes, design verification document, test plan,
decision matrix, video demonstration, and an executive summary. To the client, we will deliver
intellectual property rights, the final prototype, Solidworks files and images, project
specifications, and the design verification document.

Scope of Work Excluded
At the beginning of the semester, we established with the client that deliverables will
consist of a complete design file and working prototype. The intention behind these items is that
these documents will contain sufficient information for the client to manufacture these parts on
their own. Over the course of the year, our scope expanded slightly to include instructions for
how to use the device, but this is a very minor addition to the project.
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Figure 4. Block diagram of airflow through the QuickCough device. Air starts at the ventilator, travels into the input of the device, and will travel
through the device to the lungs if the safety guard is in act or will stop if the button is compressed and the silicone tubing is sealed.

Performance Test Results
From our testing at Akron Children’s Hospital with our mentor, Ms. Terry Volsko, we
found that the QuickCough device was able to generate a viable waveform on the lung simulator
that was sufficient to seal the airway shut and create a negative pressure in the user’s lungs.
Furthermore, upon releasing of the plunger to allow air to enter the lungs again, the plunger
quickly returned to a neutral position to restore airflow back to the levels that it was at before
occlusion (Figure 5). While these two results were anticipated before testing, it was not expected
that the device would weigh almost 6 times greater than the average attachment. Previous
estimates for the weight of the device had only included the 3D printed plastic housing. When
we discovered that the housing itself could not create a sufficient seal, the silicone tubing, twopart housing that is attached with a total of five screws, and the safety cage were added to the
design. Each component is required to carry out the complete functions of the device while still
remaining safe for the client. As expanded upon in Section XIII Future Work, the weight of the
device could be reduced in future versions of the device.
Another customer requirement that we failed to meet was creating a way for the user to
verify that the device created an airtight seal. The current technique that the client uses for this
process allows for the user to feel the pressure that is generated in the lungs on their thumb.
While it is not explicitly necessary for the function of the device, by assessing the pressure
generated in the lungs the user is able to verify that the device is functioning normally, and that
maximum mucous secretion is achieved.
It was also expected that the entire device would be 3D-printed in order to allow quick
and cheap manufacturing for the user with minimum processing. With the addition of screws and
silicone tubing, the device is no longer entirely 3D printed. Greater than 80% of the device is 3D
printed but requires post-processing of the device and some fine maneuvering is required to clear
out all of the extra plastic material. The addition of the silicone tubing ensures that an airtight
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seal is created every time but attaching the tubing into the housing is neither quick nor easy - it
takes both timing and the right touch in order to securely attach the tubing within the lower
housing. The addition of self-tapping screws into the device takes a little bit more time to
assemble the completed device but ensures that the upper and lower housings are securely
attached and reduces the likelihood that the silicone tubing will disconnect from the inner ports
of the housing.
All other test cases succeeded, including the compatibility of the device with the patient
and environment, the creation of an airtight seal, and the ability of the device to connect to the
ventilation tubing and other attachments.
Future design considerations to alleviate the issues cited above include decreasing the
overall weight of the device by removing excess material. Additionally, instead of splitting the
housing into two parts horizontally, the device could be split vertically. A vertical split would
allow for easier 3D printing as the top cap would no longer be printed in two parts and it would
become easier to attach the tubing within the housing.

Figure 5. Airway pressure during the occlusion of two breath cycles. Notably, from seconds 4-8 a waveform is maintained during occlusion,
similar to analogous devices.

Progress
While the goal of the team was to implement each and every specification, some
specifications were not reasonable to impose on the product. For example, upon development of
the initial prototype, it was discovered that an entirely 3D printed mechanism would not be
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suitable for use as intended. Upon the next iteration, a silicone tube was introduced to the design
to accomplish a relatively easy activation, airtight seal and minimal impedance of airflow.
Another specification that was not implemented was that QuickCough be no larger than the
largest ventilator adaptor provided by the client (8.5 cm x 4 cm x 4.5 cm). This specification was
not implemented because the device simply cannot be decreased in volume due to the design. In
future iterations of the QuickCough, the team could consider ways to shrink the size of the
device. A third specification that was not implemented was that when the user activated the
device by pressing the button, they would be able to feel by touch or visual aid how much
pressure is being exerted on the lungs. This aspect was brought up by the client during the design
development and due to time constraints it was not feasible to implement in the current design.
However, further iterations of QuickCough could potentially satisfy this specification. The last
two specifications that were not implemented into the design were regarding the wear on the
device. The life cycle specification was unable to be implemented due to the lack of availability
of highly accelerated life testing equipment, while the shelf life specification could not be
implemented due to time constraints for testing.

Individual Contributions
Russell was the primary contact with our mentor, Ms. Terry Volsko at Akron Children’s
Hospital. He completed substantial background and market research for the device and created
the work distribution sheet. He coordinated test plans and developed a basic understanding of the
testing model to evaluate QuickCough’s performance once data had been collected.
Mariah helped with the data collection with Ms. Volsko at Akron Children’s for the
device, interpreted the data gathered from the testing machines, helped with designing the
prototypes through iterations, developed and maintained the Gantt chart for the entire product
development cycle, developed the decision matrix selecting a prototype, created the bill of
materials of the device, and worked with an advisor to create with a safety feature for the device.
Sydney met with the customer for the initial meeting in order to develop the customer
requirements document, assisted in designing the newest iteration of the device, completed our
market analysis, documented and organized a majority of the DHF, created the specification
document, ordered the silicone tubing, and organized and maintained the team google drive.
Madison served as the primary contact point with the client, created the design
verification document, recorded meeting minutes during all team meetings, developed the MOU
and received sign-off from the client, created the block diagram of how the device’s function,
assisted with testing at Akron Children’s, and met with the client several times.
Sean did the majority of the CAD drawings for the device throughout all iterations. He
was the primary contact with Steve Paterson for 3D printing the device, investigated
manufactured valves to improve the device design, met with Dr. Willits to come up with the
silicone tubing addition, and ordered the magnets and tubing for the device.

Financial Considerations
Overall, Cough-Start costs about $36 to manufacture (Table A), includeing the cost of
the 3D print, self-tapping screws, magnets, and tubing. Looking at the other devices mentioned
above, Cough-Start is actually the second cheapest (Table B). However, the majority of the price
for Cough-Start comes from the price of the magnets. Nonetheless, the time required to make the
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device has the majority of the time spent in the 3D printing process. The actual assembly of the
device is relatively quick. This is the case because the idea for the device is that it would be
possible for the end-user to manufacturer so the price for manufacturing would not be an issue
allowing the product to stay cheaper.
Table A. Pricing for the different components of the device. Prices listed here are the pricing
needed to make exactly one of the device.
Part

Amount required

Price per part

Total Cost of
Parts

Overall 3D print cost in
Raptor PLA

0.15 lb

$32.99/lb

$4.95

No. 4 self-tapping screws

5

$9.65/50 screws

$0.97

Silicone tubing

2.5 in

$5.60/24 in

$0.58

Magnets

4

$7.26/magnet

$29.04

Table B. Condensed product comparison table between the QuickCough device, mechanical
insufflation-exsufflation (MI-E), Bag-Valve Mask (BVM), and Intermittent Positive Pressure
Breathing (IPPB) used in proximal cough assistance. Popular producers are listed in the
Company column. Four important customer needs are used for the comparison, including: the
manual nature of the device, comfort during use, cost, and portability.
Product

Company

Manual

Comfortable

Expensive

Portable

Quick-Cough

—

YES

YES

NO

YES

MI-E

Respironics, Hill-Rom,
Phillips, Emerson

NO

NO

YES

NO

BVM

Medline Industries, Ambu,
Moore–
Medical, MCR Medical

YES

NO

NO

YES

IPPB

Axcent Medical, Air
Liquide Healthcare,
InterSurgical, Hill-Rom

NO

NO

YES

NO

Summary Feasibility Discussion
The need identified at the beginning of the effort was to convert the client’s technique for
increased efficiency of secretion expulsion into a physical product which could live in line with
his ventilator tubing and port. The technique that was used by the client consisted of him
detaching himself from the ventilator and covering the ventilator port with his thumb while the
suctioning assembly was in use. The QuickCough device replicates the thumb of the client by
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completely sealing airflow into the tracheostomy port and generating a negative pressure within
the lungs. Additionally, QuickCough can be attached to the ventilator port, tubing and specific
attachments (humidifier, inhaler, etc.). This alone proves that the need identified at the beginning
of the effort was satisfied. However, it is important to note that certain design specifications were
unable to be met and therefore requires further iterations of QuickCough to be developed.
Currently, QuickCough is considered a prototype for a variety of reasons. The first being
that QuickCough demonstrates multiple functional aspects of the design instead of just one
(therefore differentiating it from a proof-of-concept model) [38]. A second reason is that
additional testing must be completed to ensure that there are no errors present in the design so
that final product construction can be competed [38]. Also, certain product specifications were
unmet and are important to satisfy in order for QuickCough to enter the market and be put on
patients.

Future Work
This device has room for development in future iterations, particularly in cases of mass
production and increased budget. One customer requirement left unfilled was the request for the
device to “allow the user to know how much pressure is being applied when it is activated.” The
current method of achieving this action is the inclusion of an open hole in the device. The patient
or caregiver can place their thumb over this hole to feel the pressure change. Because the team
wanted a continuous, closed, and quasi-permanent pathway from the ventilator to the patient, the
device has no open hole. However, in a high tech, high budget iteration, a pressure sensor and
user interface could also achieve this result. While expensive, the addition of the pressure sensor
could introduce a momentous safety feature: the ability to detect and alert others if the patient is
no longer receiving ventilation. This feature would be critical for patients who suffer from
neuromuscular disorders, who may helpless to correct an airway blockage. A pressure sensor and
user interface with an accompanying alarm feature would help give caregivers more time to
correct blockages, saving patient lives. Further, this feature would help caregivers optimize
pressure differences in the secretion expulsion process while maintaining patient comfort and
cleanliness.
This device could also be improved by making it smaller and, with the addition of a
pressure sensor, could improve the patient’s comfort as the device is always connected to the
ventilation tubing and resting near the patient’s neck and head. Future work should also go into
researching a better closure solution for the safety cage. Currently, magnets were used to close
the safety cage. These magnets were costly, accounting for 85% of the product cost, which was
acceptable with the current device, as this safety feature was critical to the success of the device.
However, the closure mechanism can be optimized for cost. Finally, future work could include
decreasing the amount of force that is required to close the airway. While we did not find an
exact value for the force required to compress the button, it seems to be larger than our goal of
12.9 N.

Discussion, Conclusions, Lessons Learned, and Recommendations
The device has gone through several major design revisions from when it was first
drafted. Initially the device started out as a component similar to what was already a part of the
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entire suctioning assembly. However, with time, many issues were found that needed to be
solved. These issues were all essentially solved by introducing a silicone tube. However, to
accommodate for the tube, the device had to become larger and became less like the part already
present on the assembly. By using this version, it was possible to gather test data to show that the
device was capable of producing the necessary seal. However, the device was not without issues.
The device did not have an intrinsic safety precaution built into the main body assembly, so a
safety cage had to be developed, detached from the rest of the device. This addition increased the
overall bulk of the entire device. It would be recommended for future iterations of the device to
avoid having this extra bulk on the top and to instead find a way to incorporate it into the the
design of the main body.
One of the biggest lessons from this project was the importance of deadlines and how,
even with impending deadlines, design iterations can still be created. If we were to do this
project again or create a second version of the QuickCough device, we would work to complete
brainstorming by October, have an initial prototype before winter break, and begin creating
iterations of the prototype and testing as soon as classes began again in January.
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Appendices
A. Design Verification Matrix
Test
Case
ID

Test Case

Description

Actual Output

Pass/Fail

1

device comes with
instructions or graphics
on the device to ensure
proper use

Instructions are provided with the
device

Graphical instruction document

Pass

2

device is easily
manufactured via 3D
printing

3

the device is easy to
replace

The device takes less than 24 hours The device takes approximately
to 3D print and costs less than $30
24 hours to print and costs
to replace
approximately $26 to print

Pass

4

it is easy to use and not
difficult to train people
to use

It takes a new user less than 60
2 human factors tests proved
seconds to comprehend how the
healthcare providers could
device works and how it should be
understand in 60 seconds or less
used

Pass

the device is 3D printed

The device is not entirely 3D
printed (as tubing and screws are Acceptable
present) and needs to be
Failure
processed by an expert

Measurement
5

device is small

6

device is easy to
transport

7

device is light

Device is no larger than the largest The device has a length of 9.79
Acceptable
attachment that our client provided cm, width of 4.10 cm, and height
Failure
us with: 8.5 cm x 4 cm x 4.5 cm
of 5.26 cm
the device can easily fit within a
coat pocket (10 cm x 8 cm)

The device fits within a coat
pocket that is 10 cm x 8 cm

Pass

device weighs less than 11.91217 g
(the mean weight of provided
Device weighs approximately 70
ventilator equipment grams
tracheostomy port & ventilator
attachments)

Fail

Raptor, silicone, and the screws do
not cause irritation to skin

Pass

Material Analysis
8

device is biocompatible

All are biocompatible (Sydney
has research articles)
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9

device is compatible
with air

10

device is compatible
with water

11

device can withstand
machine washing in a
dishwasher

12

the casing and tubing remains
the device maintains full
completely intact and functional
functionality when exposed to air
when it comes into contact with air
the casing and tubing remains
completely intact and functional
when it comes into contact with
water
the casing and tubing remains
completely intact and functional
after going through a dishwasher
cycle. The device will be seperated
in the dishwasher, top rack, with
dishwashing detergent

device is disposable after The device is non-hazardous waste
a certain period of use and can be disposed in a trash can

Pass

the device maintains full
functionality when exposed to
water

Pass

Device maintains functionality
after dishwashing

Pass

Non hazardous waste

Pass

13

there are no electrical
components to this
device

there are no electrical components
on the device

no electrical components are in
the device

Pass

14

data is not collected
from this device

data is not collected from this
device

no data collected by device

Pass

The device is able to block
airflow in 0.1 seconds

Pass

The device is able to mimic a
pressure waveform seen in
Figure 1, "Airway Pressure
During Device Occlusion."

Pass

Safety cage prevents lock in
closed position when not in use

Pass

Occluding the airway

15

16

17

It should take < 1 second for a
complete seal to be reached after
airway is
activating the device. From the
instantaneously blocked time the button was compressed to
when the user wishes to the time that the airflow became
close the airway
stable again, occluded flow
waveform formed is < 1 second
difference
When attached to the artificial
lungs, a smaller pressure waveform
is created with the occluded airway
device will create a
than when the device is open and
pressure waveform
the airway is not occluded. The
pressure waveform is similar to
that found for similar devices
there is a way to ensure
that the device will
never lock in the closed
position

The device will never be in a
locked position unless a person is
actively and intentionally pushing
on it
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when compressed and released, it
will take the button less than 5
seconds to completely return to
resting position

18

silicone is strong enough
to push button back up

19

Equipment for testing
the amount of force required to
unavailable. Anecdotal human
not much force is needed compress the button should be less
factors testing indicated the
Acceptable
to press down on the
than 12.9 N (the force required to
device required slightly too much
failure
button
press a key on a computer
force to close, but did not provide
keyboard)
undue burden

20

to press down on the
a thumb indent is present to ensure
button, there is a thumb
comfort for the user when they
indent for the comfort of
press down on it
the user
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user must be able to feel
how much pressure is
being applied when the
button is pressed down

22

23

the device does not leak
any air

air flow is not restricted
through the device

when the user compresses the
button, they are able to feel by
touch or visual aid how much
pressure is being exerted on the
lungs
The device is place with one end
underwater and a tube attached to
the end sticking out to the water.
When air is blown into the device
and the button is compressed, no
bubbles are generated
the breath that passes through the
device is not constricted by the
device. The non-occluded breaths
from our measurements match
normal breath patterns that one
would expect from a child with a
neuromuscular disorder

Device took 8 seconds to return
to neutral position

Acceptable
failure

a thumb indent is present

Pass

No tactile or electronic pressure
feedback

Fail

No bubbles are generated, which
means that no air passes through
the device

Pass

Airflow is maintained when
device is inactive. This is
validated during the first and last
3 breath cycles in Figure 1 of the
Final Report, "Airflow Pressure
During Device Occlusion."

Pass

The device fits in line with the
tracheostomy tubing

Pass

Fit with attachments

24

The device connects snuggly with
the ventilation tubing and will not
the device fits in line
easily disconnect so that the user
with the ventilation tube
can keep the device in line with the
ventilation tubing all day

25

The device will fit in line with the
The device attaches to other
device will fit with other ventilation system and attachments
tracheostomy attachments on the
ventilation tube adaptors can fit on either side of the device
smaller port only
Are there standards for this?

Pass

24

Wear on the device

26

27

device can withstand a
life cycle of 1 month
before needing to be
replaced

The device will perform at the
same level as it had before testing
after a simulated month's use of
wear (1000 compressions)

Acceptable
Failure

The device, when left unused, will
shelf life of the device is
Equipment for highly accelerated Acceptable
still work at full capacity after two
2 years
life testing unavailable.
Failure
years
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B. SolidWorks Figures

Exploded view of device with all component

Assembled view of device

Top part of housing assembly

Top cap of plunger component

Bottom part of housing assembly

Plunger component

One half of the safety cage
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C. Graphical Instruction

QUICKCOUGH
Cough assist permanently inline with ventilator for use at home and on
the go.

ADVISORIES
Do not detach patient ventilator. Ensure safety cage removal before use
and replacement upon completion. For sanitation, dishwash at highest
temperature setting with antibacterial detergent. Sanitize at every
tracheostomy port change, every 3-4 days. Replace device every 2-3
weeks. Shelf life: 2 years.

DIRECTIONS
1. Maintain device in neutral
position inline with
ventilator (Figure 1)
2. Insert suctioning equipment
into patient tracheostomy
port
3. Depress plunger to block
airflow completely
Maintain force no longer
than 15 seconds
(Figure 2).
4. Suction secretions
5. Elevate plunger to neutral
position.

6. Remove suctioning
equipment.

Figure 1. Neutral position

Figure 2. Activated position
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D. MATLAB data extraction code
A=importdata('data2.rwa');
Time_import=A.data(:,1);
T_start=find(Time_import==74);
T_end=find(Time_import==85);
Time=Time_import(T_start:T_end,:);
Time_shift=linspace(0,12,length(Time));
AirwayPressure=A.data(T_start:T_end,2);
plot(Time_shift,AirwayPressure)
title('Airway Pressure During Device Occlusion')
xlabel('Time (s)')
ylabel('Pressure (cmH20)')
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E. Drawings of the Individual 3D printed parts
All dimensions shown are in millimeters

Top part of main assembly

Bottom part of plunger component

Bottom part of main assembly

Safety Cage

Top part of plunger component

